Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by...
  • fizzle@quokk.auEnglish
    1·
    4 hours ago

    That’s not really “eugenics” as I understand the term but whatever.